Chronic pain study in severe hemophilia A
Part of Blood & lymphatic, Genetic & congenital, Pain clinical trials.
This study looks at chronic pain in people with severe hemophilia A. It aims to understand pain better through questionnaires and joint health checks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have severe hemophilia A (factor VIII less than 1%).
- You do not have inhibitors to factor VIII right now.
- You have been on bispecific antibody treatment for at least 3 months.
- You have joint damage in at least two lower-limb joints with a score of 5 or more on the Haemophilia Joint Health Score.
- You can understand and fill out questionnaires on your own.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an educational program to help people with hemophilia manage chronic joint pain better. Participants will learn pain management skills that may improve daily comfort and quality of life.
This study looks at how prophylactic treatment for hemophilia affects your daily life, sleep, and feelings about your health. It compares different types of clotting factor concentrates to see if one is easier to manage than the other.
This study uses ultrasound to check if joints that are currently healthy stay healthy in people with hemophilia A who are taking emicizumab (Hemlibra) as their regular treatment. It aims to see if this treatment helps prevent joint damage over time.
This trial tests a program to help adults with haemophilia-related joint pain learn skills to manage pain better. It may help you feel more in control of your pain and improve your daily life.
This study looks at how many adults with moderate or severe hemophilia A have inflammation in their joints (synovitis). It aims to better understand joint health in people with hemophilia A, including those with inhibitors or joint replacements.
This study checks joint health and bleeding risk in people with severe hemophilia A who are taking newer factor VIII treatments or emicizumab. It uses ultrasound and blood tests to see how well these therapies protect joints.
Hear when a new Hemophilia A Without Inhibitor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.